| Evaluation of clinical dosage of gatifloxacin for respiratory tract infections in elderly patients based on pharmacokinetics/pharmacodynamics (PK/PD). | |
| | |
MedLine Citation:
|
PMID: 18709533 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The efficacy and safety of gatifloxacin (GFLX) was evaluated for elderly patients with respiratory infections. Each patient received one-half (100 mg b.i.d.) or one-quarter (100 mg q.d.) of the conventional dosage of 200 mg b.i.d., after a tentative clinical dosage for GFLX was estimated based on the patient's age and body weight. The subjects were 34 patients aged 65 years or older with mild to moderate acute bronchitis, pneumonia, or chronic respiratory tract infections. The serum concentration of GFLX was measured for each patient, and population and pharmacokinetic (PPK) analysis was performed, using the Bayesian method, to calculate the AUC and maximum drug concentration (Cmax). The overall efficacy rate of GFLX for 33 patients was 87.9% (29/33 patients). GFLX was effective for 75.0% (6/8 patients) in the 100-mg dosage group and 92.0% (23/25 patients) in the 200-mg dosage group. The clinical efficacy was 90.0% (9/10 patients) for acute bronchitis, 86.7% (13/15 patients) for pneumonia, and 87.5% (7/8 patients) for chronic respiratory tract infections. The bacterial eradication rate was 85.7% (12/14 patients). No adverse events or laboratory abnormalities were observed. The AUC values were 11.2-37.5 microg.h/ml and 12.7-111 microg.h/ml for the 100-mg and 200-mg dosage groups, respectively, and the Cmax values were 1.28-3.02 microg/ml and 0.72-6.35 microg/ml, respectively, for the two groups. These results suggest that the dosage of GFLX examined in this study is clinically useful in elderly patients aged 65 or older with acute bronchitis, pneumonia, or chronic respiratory tract infections. The results of PPK analysis with the dosage management also support the efficacy of GFLX. |
| | |
Authors:
|
Yoshihito Niki; Koichiro Yoshida; Naoyuki Miyashita; Mikio Oka; Hiroki Hara; Michihiro Kishimoto; Niro Okimoto; Masayoshi Kawanishi; Masatoshi Uno; Takayuki Kamao; Hirohide Yoneyama; Junichi Nakamura; Makoto Kimura; Masatoshi Watanabe; Takeshi Tanimukai; Osamu Moriya; Toshiharu Matsushima |
Related Documents
:
|
18632493 - Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adu... 3861973 - Renal failure with potassium-sparing diuretics. 9095123 - Evidence for early supply independent mitochondrial dysfunction in patients developing ... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study Date: 2008-08-17 |
Journal Detail:
|
Title: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Volume: 14 ISSN: 1341-321X ISO Abbreviation: J. Infect. Chemother. Publication Date: 2008 Aug |
Date Detail:
|
Created Date: 2008-08-18 Completed Date: 2008-11-06 Revised Date: 2013-04-24 |
Medline Journal Info:
|
Nlm Unique ID: 9608375 Medline TA: J Infect Chemother Country: Japan |
Other Details:
|
Languages: eng Pagination: 296-304 Citation Subset: IM |
Affiliation:
|
School of Medicine, Department of Clinical Infectious Diseases, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan. niki@med.showa-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Anti-Bacterial Agents / administration & dosage*, pharmacokinetics Dose-Response Relationship, Drug Female Fluoroquinolones / administration & dosage*, pharmacokinetics Humans Male Microbial Sensitivity Tests Respiratory Tract Infections / drug therapy*, microbiology |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 0/Fluoroquinolones; L4618BD7KJ/gatifloxacin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An outbreak of measles in Saitama City in 2007. What is the vaccination strategy to eliminate measle...
Next Document: Retroperitoneal abscess perforating into the thoracic cavity in an immunocompromised host.